Our Products
Eisai positions "neurology" and "oncology" as two strategically important areas where we can discover "Ricchi", areas where patients true needs remain unmet and we can become a front-runner. Accordingly, we are promoting drug discovery activities in these two areas.
In addition, Eisai is committed to maximizing value for patients by developing additional formulations / expanding indications of our four global brands: Halaven®, Lenvima®, Fycompa®, and BELVIQ®.
In the neurology area, our in-house discovered and developed antiepileptic drug Fycompa® is approved as an adjunctive therapy for partial-onset seizures in over 55 countries including Japan, the United States, in Europe and in Asia. It is also approved for use as monotherapy for the treatment of partial onset seizures (with or without secondarily generalized seizures) in patients 4 years of age and older in the United States. In addition, Fycompa is approved as an adjunctive therapy for primary generalized tonic-clonic seizures in over 50 countries including Japan, the United States, in Europe and in Asia. Aricept® was first launched in January 1997 in the United States and is now approved in over 100 countries worldwide. Moreover, as a leading pharmaceutical company in the development of dementia treatments, we are also expanding our activities to promote early diagnosis and early treatment of dementia.
In the oncology area, our in-house discovered and developed anticancer agent Halaven has been approved for use in the treatment of breast cancer in over 65 countries and also for use in the treatment of malignant soft tissue sarcoma in over 50 countries. Lenvima, another anticancer agent discovered and developed in-house, has been approved for use in the treatment of thyroid cancer in over 50 countries, including Japan, the United States, in Europe, and in Asia. Additionally, it has been approved as combination therapy with everolimus for use in the treatment of renal cell carcinoma in over 45 countries including the United States and Europe. (In Europe, the brand name for this indication is Kisplyx®.) Regarding the third indication for use in the treatment of hepatocellular carcinoma, Lenvima was approved for this indication in Japan in March 2018, and in the United States, Europe and South Korea in August 2018, and in China in September 2018.
(Information current as of October 2018)
Major Products
| Sales Regions | |
|---|---|
| Four Global Brands
Halaven (anticancer agent) Lenvima (anticancer agent) Fycompa (antiepileptic agent) BELVIQ (antiobesity agent) |
Japan, Americas, Europe, Asia Japan, Americas, Europe, Asia Japan, Americas, Europe, Asia US |
| Pariet/AcipHex (proton-pump inhibitor) | Japan, US, Europe, China, Asia |
| Aricept (treatment for Alzheimer's disease / dementia with Lewy bodies) | Japan, US, Europe, China, Asia |
| Humira (fully human anti-TNF-α monoclonal antibody) | Japan, South Korea, Taiwan |
-
*Pariet is marketed in Japan by EA Pharma.
-
*Indication of Aricept for the treatment of dementia with Lewy bodies is approved only in Japan, the Philippines and Thailand.
(Information current as of October 2018)
Major Products by Region
| Japan | Prescription Pharmaceuticals |
|---|---|
| Humira (fully human anti-TNF-α monoclonal antibody)
Lyrica (pain treatment for neuropathic pain / fibromyalgia) Aricept (treatment for Alzheimer's disease / dementia with Lewy bodies) Methycobal (peripheral neuropathy treatment) Pariet (proton-pump inhibitor)* Lunesta (insomnia treatment) Halaven (anticancer agent) Lenvima (anticancer agent) Treakisym (anticancer agent) Elental (branched-chain amino acid preparation)* Warfarin (oral anticoagulant) Livact (osteoporosis treatment)* Fycompa (antiepileptic agent) |
|
| Consumer Healthcare (Over-the-Counter) Products | |
| Chocola BB group (including Vitamin B2 preparation Chocola BB Plus) | |
| Americas** | Lenvima (anticancer agent)
Banzel (antiepileptic agent) Halaven (anticancer agent) Fycompa (antiepileptic agent) AcipHex (proton-pump inhibitor) BELVIQ (antiobesity agent) |
| China | Methycobal (peripheral neuropathy treatment)
Stronger Neo-Minophagen C / Glycyron tablets (liver disease / allergic disease treatment) Aricept (treatment for Alzheimer's disease) Pariet (proton-pump inhibitor) |
| Europe | Halaven (anticancer agent)
Lenvima/Kisplyx (anticancer agent) Fycompa (antiepileptic agent) Zebinix (antiepileptic agent) Zonegran (antiepileptic agent) Inovelon (antiepileptic agent) |
| Asia and Latin America | Humira (fully human anti-TNF-α monoclonal antibody)
Aricept (treatment for Alzheimer's disease) Lenvima (anticancer agent) Pariet (proton-pump inhibitor) Methycobal (peripheral neuropathy treatment) Halaven (anticancer agent) Fycompa (antiepileptic agent) |
-
*Marketed by EA Pharma.
-
**The U.S. is the only country in the Americas where Eisai markets AcipHex and BELVIQ.
(Information current as of October 2018)
